PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10771452-5 2000 IC50 values for the inhibition of specific probe substrates for CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, by ziprasidone, risperidone and 9-hydroxyrisperidone were also determined using human liver microsomes from three subjects. Paliperidone Palmitate 140-160 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 89-95 11791898-1 2001 OBJECTIVE: Risperidone is known to be biotransformed to its active metabolite, 9-hydroxyrisperidone, by the polymorphic CYP2D6 in Caucasians. Paliperidone Palmitate 79-99 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 120-126 11791898-2 2001 This study aimed to investigate the relationship between the CYP2D6*10 allele and the plasma levels of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. Paliperidone Palmitate 119-139 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 61-67 11560868-1 2001 The antipsychotic agent risperidone, is metabolized by different cytochrome P-450 (CYP) enzymes, including CYP2D6, to the active 9-hydroxyrisperidone, which is the major metabolite in plasma. Paliperidone Palmitate 129-149 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 107-113 11560868-2 2001 Two enantiomers, (+)- and (-)-9-hydroxyrisperidone might be formed, and the aim of this study was to evaluate the importance of CYP2D6 and CYP3A4/CYP3A5 in the formation of these two enantiomers in human liver microsomes and in recombinantly expressed enzymes. Paliperidone Palmitate 26-50 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 128-134 11560868-5 2001 The formation of (+)-9-hydroxyrisperidone was strongly inhibited by quinidine, a potent CYP2D6 inhibitor, whereas ketoconazole, a CYP3A4 inhibitor, strongly inhibited the formation of (-)-9-hydroxyrisperidone. Paliperidone Palmitate 17-41 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 88-94 11560868-6 2001 Recombinant human CYP2D6 produced only (+)-9-hydroxyrisperidone, whereas a lower formation rate of both enantiomers was detected with expressed CYP3A4 and CYP3A5. Paliperidone Palmitate 39-63 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 18-24 12518271-9 2002 According to the present data, the evaluation of the risperidone/9-hydroxy-risperidone ratio may reflect the actual enzyme activity of CYP2D6. Paliperidone Palmitate 65-86 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 135-141 12107617-6 2002 The changes in risperidone concentrations were positively correlated to the concentration ratios of risperidone/9-hydroxyrisperidone (r(s)=0.90, P<0.01), which were closely associated with CYP2D6 genotypes. Paliperidone Palmitate 112-132 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 192-198 11360029-8 2001 The authors" findings indicate that paroxetine, a potent inhibitor of CYP2D6, may impair the elimination of risperidone, primarily by inhibiting CYP2D6-mediated 9-hydroxylation and to a lesser extent by simultaneously affecting the further metabolism of 9-OH-risperidone or other pathways of risperidone biotransformation. Paliperidone Palmitate 254-270 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 70-76 10771452-11 2000 Similar in vitro inhibition of CYP2D6 (Ki 6.9-16 microM) and CYP3A4 (Ki 64-80 microM) was obtained with ziprasidone, risperidone and 9-hydroxyrisperidone. Paliperidone Palmitate 133-153 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 31-37 10453802-2 1999 The ratio between risperidone and 9-hydroxyrisperidone characterizes cytochrome P450 2D6 (CYP2D6) status. Paliperidone Palmitate 34-54 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 69-88 10639689-0 1999 Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Paliperidone Palmitate 79-99 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 0-19 10639689-1 1999 The role of the polymorphic cytochrome P450 2D6 (CYP2D6) in the metabolism of risperidone to its major active metabolite, 9-hydroxyrisperidone (9-OH-risperidone), has been documented after single oral doses of the drug. Paliperidone Palmitate 122-142 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 28-47 10639689-1 1999 The role of the polymorphic cytochrome P450 2D6 (CYP2D6) in the metabolism of risperidone to its major active metabolite, 9-hydroxyrisperidone (9-OH-risperidone), has been documented after single oral doses of the drug. Paliperidone Palmitate 122-142 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 49-55 10639689-1 1999 The role of the polymorphic cytochrome P450 2D6 (CYP2D6) in the metabolism of risperidone to its major active metabolite, 9-hydroxyrisperidone (9-OH-risperidone), has been documented after single oral doses of the drug. Paliperidone Palmitate 144-160 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 28-47 10639689-1 1999 The role of the polymorphic cytochrome P450 2D6 (CYP2D6) in the metabolism of risperidone to its major active metabolite, 9-hydroxyrisperidone (9-OH-risperidone), has been documented after single oral doses of the drug. Paliperidone Palmitate 144-160 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 49-55 10639689-2 1999 In this study, the influence of the CYP2D6 polymorphism on the steady-state plasma concentrations of risperidone and 9-OH-risperidone was investigated. Paliperidone Palmitate 117-133 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 36-42 10639689-8 1999 The risperidone/9-OH-risperidone ratio was strongly associated with the CYP2D6 genotype, with the highest ratios in PM (median 0.79). Paliperidone Palmitate 16-32 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 72-78 10639689-11 1999 In conclusion, the steady-state plasma concentrations of risperidone and the risperidone/9-OH-risperidone ratio are highly dependent on the CYP2D6 genotype. Paliperidone Palmitate 89-105 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 140-146 10453802-2 1999 The ratio between risperidone and 9-hydroxyrisperidone characterizes cytochrome P450 2D6 (CYP2D6) status. Paliperidone Palmitate 34-54 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 90-96 7545821-1 1995 The hydroxylation of the new antipsychotic drug risperidone to its main, active metabolite 9-hydroxyrisperidone is catalyzed by the hepatic cytochrome P450 enzyme CYP2D6, and cosegregates with the polymorphic hydroxylation of debrisoquin. Paliperidone Palmitate 91-111 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 163-169 10048600-6 1999 A correlation study using a panel of human liver microsomes showed that the formation of 9-hydroxyrisperidone is highly correlated with CYP2D6 and 3A activities. Paliperidone Palmitate 89-109 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 136-142 10048600-8 1999 This observation is confirmed by the findings that both quinidine (inhibitor of CYP2D6) and ketoconazole (inhibitor of CYP3A4) can inhibit the formation of 9-hydroxyrisperidone. Paliperidone Palmitate 156-176 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 80-86 7690693-2 1993 The formation of the equipotent major metabolite, 9-hydroxyrisperidone, exhibited CYP2D6-related polymorphism. Paliperidone Palmitate 50-70 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 82-88 32476097-0 2020 Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach. Paliperidone Palmitate 73-93 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 107-113 33400943-6 2021 RESULTS: The risperidone Cmax,ss, Cmin,ss, AUC0-tau,ss, and the ratio of risperidone to 9-hydroxyrisperidone (9-OH-R) in CYP2D6 intermediate metabolizers (IMs) were significantly different compared with those in normal metabolizers (NMs) in both the LY03004 and Risperdal Consta groups (P < 0.05). Paliperidone Palmitate 88-108 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 121-127 32519344-1 2020 BACKGROUND: Risperidone is a second-generation antipsychotic drug metabolized to an active metabolite, 9-hydroxyrisperidone, primarily by cytochrome P4502D6 (CYP2D6) and to a lesser extent by CYP3A4. Paliperidone Palmitate 103-123 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 138-156 32519344-1 2020 BACKGROUND: Risperidone is a second-generation antipsychotic drug metabolized to an active metabolite, 9-hydroxyrisperidone, primarily by cytochrome P4502D6 (CYP2D6) and to a lesser extent by CYP3A4. Paliperidone Palmitate 103-123 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 158-164 32519344-11 2020 CONCLUSION: Genetically defined impaired CYP2D6 activity is associated with increased exposure of both risperidone and risperidone+9-hydroxyrisperidone in adults receiving oral formulations. Paliperidone Palmitate 131-151 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 41-47 32682874-4 2021 CYP2D6 normal/ultrarapid metabolizers (NM/UM) (vs. other) had lower risperidone (29%) and active moiety levels (24%) (9-OH-risperidone not affected). Paliperidone Palmitate 118-134 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 0-6 32476097-2 2020 Based on the genetic polymorphism of cytochrome P 450 (CYP) 2D6 genetically and age-related changes cause differences in the pharmacokinetics of risperidone and 9-hydroxyrisperidone. Paliperidone Palmitate 161-181 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 37-63 28133766-5 2017 RESULTS: CYP2D6 poor and intermediate metabolizers had lower formation rates of 9-hydroxy-risperidone (94% and 76% lower, respectively) compared to the extensive CYP2D6 metabolizers. Paliperidone Palmitate 80-101 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 9-15 31359271-0 2020 Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes. Paliperidone Palmitate 100-120 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 134-153 31359271-3 2020 The goal of this study was to develop a physiologically based pharmacokinetic (PBPK) model considering the CYP2D6 genetic polymorphism for risperidone and 9-hydroxyrisperidone (9-OH-RIS) taking CYP3A4 into account. Paliperidone Palmitate 155-175 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 107-113 31000417-1 2019 BACKGROUND: The polymorphic CYP2D6 enzyme metabolises the antipsychotic drugs risperidone and aripiprazole to their active metabolites, 9OH-risperidone and dehydroaripiprazole. Paliperidone Palmitate 136-151 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 28-34 30093744-8 2018 Results: The number of CYP2D6*4 alleles affected the plasma levels of risperidone, 9-hydroxyrisperidone at 6 weeks of treatment but not at 12 weeks. Paliperidone Palmitate 83-103 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 23-29 26780783-0 2017 Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder. Paliperidone Palmitate 79-99 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 10-16 28520384-2 2012 Risperidone is metabolized to the active metabolite 9-hydroxyrisperidone by the enzyme CYP2D6 and to a lesser extent by CYP3A4. Paliperidone Palmitate 52-72 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 87-93 26780783-8 2017 Additionally, the plasma concentration of risperidone/9-OH risperidone ratio in patients with a CYP2D6 activity score of 0.5 were significantly higher than those with a CYP2D6 activity score of 2 (p = 0.04). Paliperidone Palmitate 54-70 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 96-102 26780783-11 2017 The findings indicate that CYP2D6 polymorphisms affect the plasma concentrations of risperidone and the risperidone/9-hydroxyrisperidone ratio. Paliperidone Palmitate 116-136 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 27-33 27145399-1 2016 The aim of this study was to investigate the impact of ageing on serum concentrations of risperidone and 9-hydroxyrisperidone in patients with known CYP2D6 genotype. Paliperidone Palmitate 105-125 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 149-155 27738718-0 2017 Erratum to: Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Paliperidone Palmitate 151-163 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 49-55 27942231-5 2016 Several studies suggested that CYP2D6 polymorphisms were associated with plasma concentration of risperidone, 9-hydroxyrisperidone, and active moiety but did not impact on clinical outcomes. Paliperidone Palmitate 110-130 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 31-37 26418700-6 2016 The sensitivity, specificity, positive predictive value, and negative predictive value (confidence interval) of a risperidone/9-hydroxyrisperidone ratio >1 to predict a CYP2D6 poor metabolizer genotype were 91% (76%-97%), 86% (83%-89%), 35% (26%-46%), and 99% (97%-100%), respectively. Paliperidone Palmitate 126-146 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 172-178 26514968-0 2016 Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Paliperidone Palmitate 139-151 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 37-43 26514968-10 2016 It was demonstrated that CYP2D6 polymorphisms affect the serum concentrations of aripiprazole (n = 18), haloperidol (n = 11), risperidone (n = 20), and zuclopenthixol (n = 6), while no influence was seen on the paliperidone serum concentrations (n = 31). Paliperidone Palmitate 211-223 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 25-31 26944100-7 2016 The plasma concentration of risperidone and risperidone/9-hydroxyrisperidone ratio in the patients were significant differences among the CYP2D6 predicted phenotype group (P = 0.001 and P < 0.0001 respectively). Paliperidone Palmitate 56-76 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 138-144 26944100-8 2016 Moreover, the plasma concentration of risperidone and risperidone/9-hydroxyrisperidone ratio in the patients with CYP2D6 activity score 0.5 were significantly higher than those with the CYP2D6 activity score 2.0 (P = 0.004 and P = 0.002 respectively). Paliperidone Palmitate 66-86 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 114-120 26387027-4 2015 Pharmacokinetic parameters were derived from plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone (formed via CYP2D6 and CYP3A4), collected before and over 4 days after risperidone administration, and from steady-state plasma concentrations of armodafinil and its circulating metabolites, R-modafinil acid and modafinil sulfone. Paliperidone Palmitate 109-129 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 142-148 26129906-12 2015 CONCLUSIONS: Genetic polymorphisms of CYP2D6 play an important role in risperidone, 9-hydroxyrisperidone and active moiety plasma concentration variability, which were associated with common side effects. Paliperidone Palmitate 84-104 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 38-44 21387786-2 2010 The therapeutic action of RIS depends not only on the parent compound but also its major active metabolite, 9-hydroxyrisperidone (9-OH-RIS), and the pharmacokinetics is modified by the genetic polymorphism of CYP2D6, the main site o RIS metabolism. Paliperidone Palmitate 108-128 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 209-215 22929407-0 2012 Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents. Paliperidone Palmitate 55-75 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 88-94 22929407-5 2012 RESULTS: A 1-compartment mixture model described risperidone and (+-)-9-hydroxyrisperidone clearances for 3 CYP2D6 metabolizer subpopulations: extensive, intermediate, and poor. Paliperidone Palmitate 65-90 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 108-114 22623266-0 2012 Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1. Paliperidone Palmitate 55-75 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 106-112 22623266-1 2012 This study estimated the population pharmacokinetics of risperidone and its active metabolite, 9-hydroxyrisperidone, according to genetic polymorphisms in the metabolizing enzyme (CYP2D6) and transporter (ABCB1) genes in healthy subjects. Paliperidone Palmitate 95-115 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 180-186 22623266-10 2012 The population pharmacokinetic model of risperidone and 9-hydroxyrisperidone including the genetic polymorphisms of CYP2D6*10 and ABCB1 3435C>T as covariates was successfully constructed. Paliperidone Palmitate 56-76 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 116-122 22623266-11 2012 The estimated contribution of genetic polymorphisms in CYP2D6*10 and ABCB1 3435C>T to population pharmacokinetics of risperidone and 9-hydroxyrisperidone suggests the interplay of CYP2D6 and ABCB1 on the pharmacokinetics of risperidone and 9-hydroxyrisperidone according to genetic polymorphisms. Paliperidone Palmitate 136-156 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 55-61 22623266-11 2012 The estimated contribution of genetic polymorphisms in CYP2D6*10 and ABCB1 3435C>T to population pharmacokinetics of risperidone and 9-hydroxyrisperidone suggests the interplay of CYP2D6 and ABCB1 on the pharmacokinetics of risperidone and 9-hydroxyrisperidone according to genetic polymorphisms. Paliperidone Palmitate 136-156 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 183-189 22623266-11 2012 The estimated contribution of genetic polymorphisms in CYP2D6*10 and ABCB1 3435C>T to population pharmacokinetics of risperidone and 9-hydroxyrisperidone suggests the interplay of CYP2D6 and ABCB1 on the pharmacokinetics of risperidone and 9-hydroxyrisperidone according to genetic polymorphisms. Paliperidone Palmitate 243-263 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 183-189 21387786-2 2010 The therapeutic action of RIS depends not only on the parent compound but also its major active metabolite, 9-hydroxyrisperidone (9-OH-RIS), and the pharmacokinetics is modified by the genetic polymorphism of CYP2D6, the main site o RIS metabolism. Paliperidone Palmitate 130-138 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 209-215 19910717-0 2009 Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. Paliperidone Palmitate 82-102 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 10-16 19910717-2 2009 The present study is the first to investigate the impact of CYP2D6 genotype on serum concentrations of risperidone and 9-hydroxyrisperidone in patients using injectable long-acting risperidone. Paliperidone Palmitate 119-139 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 60-66 19440082-11 2009 In conclusion, both CYP2D6 and CYP3A5 genotypes affected plasma levels of RIS and 9-OH-RIS, whereas the active moiety levels were influenced only by the CYP3A5 genotype but not by the CYP2D6 genotype. Paliperidone Palmitate 82-90 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 20-26 19387994-1 2009 OBJECTIVE: Risperidone is converted to 9-hydroxyrisperidone by CYP2D6. Paliperidone Palmitate 39-59 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 63-69 16833023-8 2006 The CYP2D6*10 allele particularly was associated with higher serum concentrations of risperidone and the risperidone/9-OH-risperidone ratio compared with the CYP2D6*1 allele. Paliperidone Palmitate 117-133 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 4-10 18708991-1 2008 Risperidone is metabolized to its active metabolite, 9-hydroxyrisperidone, mainly by the cytochrome P450 enzymes CYP2D6 and 3A4. Paliperidone Palmitate 53-73 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 113-119 17541883-1 2007 Risperidone (R) is metabolized to 9-hydroxyrisperidone (9-OHR) by cytochrome P450 2D6 (CYP2D6). Paliperidone Palmitate 34-54 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 87-93 18708991-9 2008 The CYP2D6 genotype in these 46 patients was again associated with risperidone C/D (P = 0.001) but not with 9-hydroxyrisperidone C/D or active moiety C/D, as previously shown by our group in 37 of these patients. Paliperidone Palmitate 108-128 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 4-10 18728628-3 2008 CYP2D6 catalyzes the conversion of risperidone to the active metabolite 9-OH-risperidone. Paliperidone Palmitate 72-88 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 0-6 18728628-4 2008 The question whether CYP2D6 activity is important for the level of the "active moiety" (ie, the sum of risperidone and 9-OH-risperidone) is controversial. Paliperidone Palmitate 119-135 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 21-27 18728628-5 2008 Concentration-to-dose (C:D) ratios of risperidone and 9-OH-risperidone in 218 patients were associated with the number of concomitantly used substrates or inhibitors of CYP2D6. Paliperidone Palmitate 54-70 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 169-175 17715206-1 2007 The object of this study is to assess 1) the relationship between plasma antipsychotic drug concentration, serum prolactin levels and the clinical efficacy of risperidone, 2) the relationship between the CYP2D6 polymorphisms and metabolizing of risperidone and 3) the role of 9-hydroxyrisperidone in elevating prolactin levels. Paliperidone Palmitate 276-296 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 204-210 16833023-10 2006 Furthermore, the pharmacokinetic parameters of risperidone and the risperidone/9-OH-risperidone ratio are highly dependent on the CYP2D6 genotypes. Paliperidone Palmitate 79-95 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 130-136 15270204-3 2004 Risperidone in humans is mainly metabolized to 9-hydroxyrisperidone by the polymorphic cytochrome enzyme P450 2D6 (CYP2D6). Paliperidone Palmitate 47-67 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 115-121 16321618-2 2005 The aim of this study was to evaluate the effect of itraconazole, a CYP3A inhibitor, on the plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients in relation to CYP2D6 genotype. Paliperidone Palmitate 133-153 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 195-201 16321618-8 2005 In addition, the active moiety (risperidone plus 9-hydroxyrisperidone) also increased similarly, by 71% (P < .001) and 73% (P < .05), respectively, with itraconazole, without a significant difference between CYP2D6 genotypes. Paliperidone Palmitate 49-69 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 214-220 15565299-17 2005 CYP2D6 polymorphisms did not predict clinical response, but predicted a tendential increase in the plasma risperidone to 9-OH-risperidone ratio (0.5 +/- 0.6 vs. 1.9 +/- 1.8; p = 0.120). Paliperidone Palmitate 121-137 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 0-6 15565299-19 2005 The observed CYP2D6 polymorphisms did not contribute to altered clinical efficacy, but affected risperidone to 9-OH-risperidone ratios. Paliperidone Palmitate 111-127 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 13-19 15270204-4 2004 Plasma concentrations of risperidone and 9-hydroxyrisperidone show large interindividual variability, which may be partly related to the activity of the CYP2D6 enzyme. Paliperidone Palmitate 41-61 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 153-159 15270204-8 2004 Since risperidone/9-hydroxyrisperidone ratio strongly correlates with CYP2D6 enzyme activity and the number of CYP2D6 active genes, thus it might be a useful tool in clinical practice to estimate the possible risk of drug interactions due to impaired CYP2D6 enzyme activity. Paliperidone Palmitate 18-38 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 70-76 15270204-8 2004 Since risperidone/9-hydroxyrisperidone ratio strongly correlates with CYP2D6 enzyme activity and the number of CYP2D6 active genes, thus it might be a useful tool in clinical practice to estimate the possible risk of drug interactions due to impaired CYP2D6 enzyme activity. Paliperidone Palmitate 18-38 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 111-117 15270204-8 2004 Since risperidone/9-hydroxyrisperidone ratio strongly correlates with CYP2D6 enzyme activity and the number of CYP2D6 active genes, thus it might be a useful tool in clinical practice to estimate the possible risk of drug interactions due to impaired CYP2D6 enzyme activity. Paliperidone Palmitate 18-38 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 111-117 15260906-10 2004 The number of CYP2D6 active genes was related to the dose-corrected plasma concentration of risperidone (p < 0.05), the active moiety (risperidone plus 9-OH-risperidone) (p < 0.05) and the risperidone/9-OH-risperidone ratio (p < 0.05). Paliperidone Palmitate 155-171 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 14-20 15260906-10 2004 The number of CYP2D6 active genes was related to the dose-corrected plasma concentration of risperidone (p < 0.05), the active moiety (risperidone plus 9-OH-risperidone) (p < 0.05) and the risperidone/9-OH-risperidone ratio (p < 0.05). Paliperidone Palmitate 207-223 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 14-20 12616663-0 2003 Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. Paliperidone Palmitate 87-107 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 11-17 12616663-8 2003 The concentration ratio of risperidone to 9-hydroxyrisperidone was strongly dependent on the CYP2D6 genotypes. Paliperidone Palmitate 42-62 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 93-99 12616663-9 2003 This study suggests that CYP2D6 activity strongly influences the steady-state plasma concentrations of risperidone and risperidone/9-hydroxyrisperidone concentration ratios but is unlikely to determine enantio-selectivity in the steady-state plasma concentrations of 9-hydroxyrisperidone in the clinical situation. Paliperidone Palmitate 131-151 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 25-31 12616663-9 2003 This study suggests that CYP2D6 activity strongly influences the steady-state plasma concentrations of risperidone and risperidone/9-hydroxyrisperidone concentration ratios but is unlikely to determine enantio-selectivity in the steady-state plasma concentrations of 9-hydroxyrisperidone in the clinical situation. Paliperidone Palmitate 267-287 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 25-31 15089809-8 2004 Multiple regression analyses including CYP2D6 genotypes, sex, and age revealed that steady-state plasma concentration of risperidone correlated with the number of mutated alleles for CYP2D6 (standardized partial correlation coefficients (beta) = 0.540, P < 0.001) and those of 9-hydroxyrisperidone (standardized beta = 0.244, P = 0.038) and active moiety (standardized beta = 0.257, P = 0.027) correlated with age. Paliperidone Palmitate 280-300 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 183-189